Praxis Precision Medicines, Inc. PRAX
328.13 USD +3.37 (+1.04%)
Regular-session close
321.00 -7.13 -2.17%
After hours · Nov 13, 6:58 PM ET
315.23 Day range 328.98
164.09 52-week range 386.33
- YTD
- +11.33%
- 1 year
- +84.26%
News
globenewswire.com Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027
seekingalpha.com Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly -…
benzinga.com RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $478 RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $462 to $478.- benzinga.com Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $189 Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $188 to $189.
benzinga.com Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Lowers Price Target to $343 Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and lowers the price target from $362 to $343.- benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $826 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $826 price target.
globenewswire.com Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
benzinga.com JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700 JP Morgan analyst Tessa Romero initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight rating and announces Price Target of $700.
benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.